KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Before Jan 1, 2029 99%Führend unter 5 Optionen
Marktqualitat
43 / 100
Niedrige Qualität24h-Volumen
12 €
Liquidität
13.772,1 €
Mittlere LiquiditätSpread
7.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 13 Minuten
14. Mai 26, 02:00 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
When will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve CagriSema?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsRegeln
If the FDA approves retatrutide (LY3437943) for marketing the named outcome, then the market resolves to Yes.
Abwicklung über:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Offene Märkte
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 30.387,4 €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 652.807,7 €
- 24h-Volumen
- 3547,3 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes-0.7pt3%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 2906,5 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt97%
- Above 600059%
+2 weitere Ergebnisse
- Gesamtvolumen
- 865.320,4 €
- 24h-Volumen
- 2719,4 €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Gesamtvolumen
- 915.253 €
- 24h-Volumen
- 1382,5 €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt65%
- September41%
- June28%
- Gesamtvolumen
- 84.047,3 €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Häufige Fragen
- Wie stehen die aktuellen Quoten für Will the FDA approve retatrutide??
- Kalshi bewertet Before Jan 1, 2029 mit 99% (Stand: 9. September 2026).
- Wann wird Will the FDA approve retatrutide? entschieden?
- Will the FDA approve retatrutide? soll am 1. Januar 2027 entschieden werden.
- Wie wird Will the FDA approve retatrutide? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves retatrutide (LY3437943) for marketing the named outcome, then the market resolves to Yes.